Rxsight Inc (RXST) - Total Liabilities
Based on the latest financial reports, Rxsight Inc (RXST) has total liabilities worth $36.70 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Rxsight Inc (RXST) equity growth momentum to track the company's year-over-year net asset growth rate.
Rxsight Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Rxsight Inc's total liabilities have evolved over time, based on quarterly financial data. See Rxsight Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Rxsight Inc Competitors by Total Liabilities
The table below lists competitors of Rxsight Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kardemir Karabuk Demir Celik Sanayi ve Ticaret AS Class A
IS:KRDMA
|
Turkey | TL35.63 Billion |
|
Venus Remedies Limited
NSE:VENUSREM
|
India | Rs1.74 Billion |
|
Kumho Ind
KO:002990
|
Korea | ₩1.26 Trillion |
|
Cint Group AB
ST:CINT
|
Sweden | Skr145.95 Million |
|
Vecima Networks Inc.
TO:VCM
|
Canada | CA$129.74 Million |
|
Penns Woods Bancorp Inc
NASDAQ:PWOD
|
USA | $2.04 Billion |
|
Empire Energy Group Ltd
AU:EEG
|
Australia | AU$30.56 Million |
|
Peoples Bancorp of North Carolina
NASDAQ:PEBK
|
USA | $1.58 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Rxsight Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RXST market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rxsight Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rxsight Inc (2019–2025)
The table below shows the annual total liabilities of Rxsight Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $36.13 Million | -3.20% |
| 2024-12-31 | $37.33 Million | +68.22% |
| 2023-12-31 | $22.19 Million | -63.18% |
| 2022-12-31 | $60.26 Million | +10.62% |
| 2021-12-31 | $54.48 Million | -86.32% |
| 2020-12-31 | $398.21 Million | -4.06% |
| 2019-12-31 | $415.04 Million | -- |
About Rxsight Inc
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adju… Read more